# Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

> **NCT00399529** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 22 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **BIOLOGICAL:** Allogeneic GM-CSF-secreting breast cancer vaccine
- **DRUG:** Trastuzumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00399529
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-04-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399529, "Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00399529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*